Loading...
Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
BACKGROUND: Recently, collaboration between regulators and payers was set up and was mainly focused on evidence generation along product clinical development. However, neither the regulatory path nor the new active substance status (NASs) was considered. Granting NASs will provide the product with 8...
Na minha lista:
| Udgivet i: | J Mark Access Health Policy |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Co-Action Publishing
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4865780/ https://ncbi.nlm.nih.gov/pubmed/27226838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v2.23932 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|